SYSTEMATIC REVIEW article
Front. Microbiol.
Sec. Systems Microbiology
This article is part of the Research TopicDynamics of the Human Skin MicrobiotaView all 9 articles
Efficacy and safety of probiotics as a complementary treatment for urticaria: a systematic review and meta-analysis
Provisionally accepted
- Hunan University of Chinese Medicine, Changsha, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective: The potential of probiotics in the treatment of urticaria has garnered significant attention. However, a systematic assessment of their benefits and risks is lacking. This meta-analysis and trial sequential analysis (TSA) aim to evaluate the efficacy and safety of probiotics as a complementary treatment for urticaria. Methods: Relevant studies published before April 30, 2025, were retrieved and screened from eight public databases. The basic characteristics, outcome data, and risk of bias of the included studies were recorded. Meta-analysis and TSA were conducted using Review Manager 5.3 and TSA 0.9.5.10 Beta, respectively. Funnel plots and Egger’s test were employed to assess publication bias, while the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system was used to evaluate the certainty of evidence. Results: A total of 11 clinical trials involving 1,014 participants were included in this study. The meta-analysis revealed that, compared to antihistamines alone, the combination of probiotics and antihistamines significantly improved the urticaria relief rate (URR) (odds ratio [OR] 2.90, 95% confidence interval [CI] 1.97 to 4.28, P < 0.00001) and interferon-gamma (IFN-γ) levels (mean difference [MD] 8.12, 95% CI 6.95 to 9.30, P < 0.00001). Additionally, it reduced the urticaria activity score over 7 days (UAS7) (MD -3.29, 95% CI -3.28 to -2.75, P < 0.00001), the dermatology life quality index (DLQI) (MD -2.95, 95% CI -3.21 to -2.69, P < 0.00001), interleukin-10 (IL-10) levels (MD -1.47, 95% CI -2.01 to -0.93, P < 0.00001), adverse event rate (AER) (OR 0.39, 95% CI 0.20 to 0.77, P = 0.007), and recurrence rate (OR 0.29, 95% CI 0.14 to 0.60, P = 0.0008). The TSA confirmed the conclusiveness of the aforementioned meta-analysis results. Egger’s test indicated no significant publication bias for these outcomes. Conclusion: Probiotics not only improve clinical symptoms in patients with urticaria but may also reduce the incidence of adverse events and recurrence rates. This highlights the potential of probiotics as a complementary treatment for urticaria. However, due to the risk of bias in the existing studies, these findings need to be validated through high-quality clinical trials.
Keywords: Gut Microbiota, Meta-analysis, Probiotics, Trial sequential analysis, Urticaria
Received: 27 May 2025; Accepted: 10 Nov 2025.
Copyright: © 2025 Tan, Yu, Yin, Qin, Xiang and Yu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Danni Tan, tandanni2023@163.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.